UNSPSC 51141516: Fosphenytoin

This classification denotes an anticonvulsant agent with the molecular formula C16H13N2O6P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7VLR55452Z, chemically known as 2,4-imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, disodium salt but generally known as fosphenytoin sodium, which bears US NIH Compound Identifier 56338. European Medicines Agency schedules Fosphenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13919MIG.

Most nations schedule fosphenytoin under HS 29332100 and SITC 51572. As of Q4 2014, FOSPHENYTOIN remains the US FDA Preferred Term for this commodity. Fosphenytoin bears US NLM identifiers UMLS ID C0244656 and NCI Concept Code C65766. SMILES: P(=O)(OCN1C(=O)C(NC1=O)(C1CCCCC1)C1CCCCC1)(O)O.[NA].[NA].

UNSPSC 51141516 Fosphenytoin (Commodity) represents pharmaceutical products—anticonvulsant medications and related therapeutics—that state and local governments procure for health departments, correctional facilities, emergency medical services, and community health programs. The recent solicitations under this code and closely related pharmaceutical families show state and local buyers purchasing naloxone, generic multi-source drugs, and OTC products through competitive bidding and cooperative purchasing agreements. Issuing bodies span state health agencies (Texas Health and Human Services Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), and multistate cooperative purchasing consortiums. The work involves establishing supply contracts with manufacturers and authorized distributors, negotiating pricing structures (fixed fee, net price formats, WAC-minus models), ensuring compliance with cGMP and Drug Supply Chain Security Act standards, and arranging quarterly or ongoing delivery to multiple health facilities.

Activity concentrates in the Upper Midwest and South. Minnesota's MMCAP cooperative purchasing alliance (which includes participating Oregon jurisdictions) posted a major RFP on January 20, 2026, due March 26, 2026, seeking multiple manufacturers for generic pharmaceuticals and OTC products with delivery required by July 1, 2026; evaluation weights 75 percent on price competitiveness, with mandatory relationships through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and compliance with FDA, cGMP, and DSCSA requirements. Texas HHS issued a Request for Information (RFI) on March 27, 2026, due April 3, 2026, exploring direct-to-manufacturer prescription programs and vendor capabilities for self-insured group health plans outside traditional PBM arrangements. Seminole County, Florida released an IFB on June 30, 2026 (posted notice date), due July 26, 2023 (note: discrepancy in source dates), for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus optional one-year renewal. Recent opportunities show increasing state and local interest in cooperative purchasing, direct-manufacture relationships, and comprehensive pharmaceutical supply agreements to manage cost and supply-chain risk.